Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price target of $8.83 for the company and are anticipating that the company will post ($0.24) earnings per share for the current quarter, according to Zacks. Zacks has also assigned AzurRx BioPharma an industry rank of 195 out of 265 based on the ratings given to related companies.
Separately, HC Wainwright set a $8.00 price objective on shares of AzurRx BioPharma and gave the company a “buy” rating in a research note on Monday, October 23rd.
AzurRx BioPharma (NASDAQ:AZRX) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.13). sell-side analysts forecast that AzurRx BioPharma will post -1.06 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in AZRX. Parsons Capital Management Inc. RI raised its holdings in AzurRx BioPharma by 37.2% during the 3rd quarter. Parsons Capital Management Inc. RI now owns 254,263 shares of the company’s stock worth $1,015,000 after buying an additional 68,920 shares during the period. Ardsley Advisory Partners acquired a new stake in AzurRx BioPharma during the 2nd quarter worth approximately $141,000. Susquehanna International Group LLP acquired a new stake in AzurRx BioPharma during the 3rd quarter worth approximately $131,000. Finally, IHT Wealth Management LLC raised its holdings in AzurRx BioPharma by 15.3% during the 2nd quarter. IHT Wealth Management LLC now owns 3,498 shares of the company’s stock worth $486,000 after buying an additional 464 shares during the period. Institutional investors own 8.14% of the company’s stock.
WARNING: This article was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://sportsperspectives.com/2018/02/09/1610267.html.
About AzurRx BioPharma
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.